Z-VAD-OMe-FMK-Z-Val-Ala-Asp-OMe-FMK-DataSheet-生命科学试剂-MedChemExpress_第1页
Z-VAD-OMe-FMK-Z-Val-Ala-Asp-OMe-FMK-DataSheet-生命科学试剂-MedChemExpress_第2页
Z-VAD-OMe-FMK-Z-Val-Ala-Asp-OMe-FMK-DataSheet-生命科学试剂-MedChemExpress_第3页
Z-VAD-OMe-FMK-Z-Val-Ala-Asp-OMe-FMK-DataSheet-生命科学试剂-MedChemExpress_第4页
全文预览已结束

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEZ-VAD(OMe)-FMKCat. No.: HY-16658CAS No.: 187389-52-2Synonyms: Z-Val-Ala-Asp(OMe)-FMK分式: CHFNO分量: 467.49Sequence: Z-Val-Ala-Asp(OMe)-FMKSequence Shortening: ZVA-D(OMe)-FMK作靶点: Caspase作通路: Apoptosis储存式: Powder -80C 2 years-20C 1 y

2、earIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 100 mg/mL (213.91 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 2.1391 mL 10.6954 mL 21.3908 mL5 mM 0.4278 mL 2.1391 mL 4.2782 mL10 mM 0.2139 mL 1.0695 mL 2.1391 mL请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液,并请注意储备液的保存式和期限。体内实验请根据您的实验

3、动物和给药式选择适当的溶解案,配制前请先配制澄清的储备液,再依次添加助溶剂(为保证实验结果的可靠性,体内实验的作液,建议您现现配,当天使;澄清的储备液可以根据储存条件,适当保存;以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占):1. 请依序添加每种溶剂: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (5.35 mM); Clear solution1/3 Master of Small Molecules 您边的抑制剂师www.MedChemE2. 请依序添加每种溶剂: 10% DMSO 90% (20%

4、SBE-CD in saline)Solubility: 2.5 mg/mL (5.35 mM); Clear solution3. 请依序添加每种溶剂: 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (5.35 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Z-VAD(OMe)-FMK种可渗透细胞的不可逆 pan-caspase 抑制剂。IC50 & Target Caspase体外研究 Z-VAD(OMe)-FMK is a broad-spectrum caspase inhibitor, has been s

5、hown to inhibit the intracellularactivation of caspase-like proteases. The injection of Z-VAD(OMe)-FMK suppresses the caspase-3 activity inlung tissues, and significantly decreases the number of terminal dUTP nick-end labeling-positive cells 1. Z-VAD(OMe)-FMK is administered intraperitoneally at 1 h

6、our before and 6 hours after SAH. Expression ofcaspase-3 and positive TUNEL is examined as markers for apoptosis. Z-VAD(OMe)-FMK suppressesTUNEL and caspase-3 staining in endothelial cells, decreases caspase-3 activation, reduces BBBpermeability, relieves vasospasm, abolishes brain edema, and improv

7、es neurological outcome 2. Z-VAD(OMe)-FMK is a cell-permeable caspase inhibitor, efficiently blocks cell death induced by SMNdeficiency 3.体内研究 The survival rate of mice is prolonged significantly by the injection of Z-VAD(OMe)-FMK. All mice succumbedto LPS within 30 hours. By contrast, the mice trea

8、ted with Z-VAD(OMe)-FMK survive significantly longer and27% of the mice survived more than 7 days 1.PROTOCOLCell Assay 3 PCR products containing coding sequences for the dSMN (forward primer: 5-TAA TAC GAC TCA CTA TAGGG AAG ACG TAC GAC GAG TCG-3; and reverse primer: 5-TAA TAC GAC TCA CTA TAG GG GTG

9、GTGCTG GCT TCT TTC-3; product length, 601bps; bold and italics letters represent T7 promoter sequences)and control Drosophila Presenilin (dPsn) gene (forward primer: 5-TAA TAC GAC TCA CTA TAG GG TGGCT GCT GTC AAT CTC-3; and reverse primer: 5-TAA TAC GAC TCA CTA TAG GG CGA TAG CAA CGCTTC TTG-3; produ

10、ct length: 543bps) are obtained and gel-purified. Double-stranded RNAs (dsRNA) aregenerated by transcription with Ribomax T7 Transcription kit and digested with Rnase-free DNase. ThedsRNA products are ethanol precipitated and annealed by incubation at 65C for 30 min and then slowlyallowed to cool at

11、 room temperature. The annealed dsRNA products are analyzed on a 1% agaorse gel toensure the majority of dsRNA existed as a single band. The dsRNA (2 g) and/or plasmid DNAs (2 g) areintroduced into cells by using Cellfectin. Caspase inhibition is achieved by using 50 M of Z-VAD(OMe)-FMKin the cultur

12、e medium 3.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 12/3 Master of Small Molecules 您边的抑制剂师www.MedChemEAdministration 12 Mice used in this study are 5- to 6-week-old (20 to 22 g) ICR males. Mice are injected with 30 mg/kg LPSfrom E. co

13、li serotype O111:B4 through the tail vein. A single intravenous injection of Z-VAD(OMe)-FMK (0.25mg) is made 15 minutes before LPS injection, followed by three intravenous injections of Z-VAD(OMe)-FMK(0.1 mg each) per hour. Control mice are injected with the same volume of 1% DMSO in sterile saline.

14、Rats 2Male Sprague-Dawley rats weighing 300 to 350 g are anesthetized with -chloralose (40 mg/kg IP) andurethane (400 mg/kg IP). Animals are intubated, and respiration is maintained with a small animal respirator.Rectal temperature is maintained at 370.5C with a heating pad. The left external caroti

15、d artery is isolatedand a 4.0 monofilament nylon suture is inserted through the internal carotid artery to perforate the middlecerebral artery. SAH is confirmed at autopsy in each rat. Sham-operated rats underwent the sameprocedures except that the suture is withdrawn after resistance is felt. Z-VAD

16、(OMe)-FMK (50 M per 0.3 mL)is injected intraperitoneally at 1 hour before and 6 hours after SAH induction. In vehicle group, ratsunderwent SAH induction and are treated with the same volume of vehicle (DMSO diluted in physiologicalbuffer solution). No treatment is applied in sham-operated animals.MC

17、E has not independently confirmed the accuracy of these methods. They are for reference only.户使本产品发表的科研献 Cell. 2018 Sep 6;174(6):1477-1491.e19. Nat Commun. 2018 Jan 30;9(1):435. Autophagy. 2019 Jun 16:1-16. Theranostics. 2019 May 31;9(13):3732-3753. Elife. 2017 Dec 12;6. pii: e30590.See more custome

18、r validations on HYPERLINK / www.MedChemEREFERENCES1. Kawasaki M, et al. Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspaseinhibitor. Am JPathol. 2000 Aug;157(2):597-603.2. Park S, et al. Neurovascular protection reduces early brain injury after subarachnoid hemorrhage. Stroke. 2004 Oct;35(10):2412-7.3. Ilangovan R, et al. Inhibition of apoptosis by

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论